Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (171-180 of 199) with videos related to

Pageof 20
Sort By:
The Journal of Pathology|October 15, 2013
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cellsYihui Fan, Ningling Ge, Xiaosong Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 TherapyMario Giuliano, Huizhong Hu, Yen-Chao Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2019
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Carmine De Angelis, et al.
Science Translational Medicine|March 28, 2014
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancerThushangi N Pathiraja, Shweta R Nayak, Yuanxin Xi, et al.
Breast Cancer Research : BCR|January 10, 2015
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasisMario Giuliano, Sabrina Herrera, Pavel Christiny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2019
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without ChemotherapyCarmine De Angelis, Chandandeep Nagi, Cliff C Hoyt, et al.
Developmental Cell|April 20, 2021
The bone microenvironment increases phenotypic plasticity of ER<sup>+</sup> breast cancer cellsIgor L Bado, Weijie Zhang, Jingyuan Hu, et al.
Molecular Cancer Research : MCR|August 18, 2019
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast CancerVidyalakshmi Sethunath, Huizhong Hu, Carmine De Angelis, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Science Advances|July 25, 2020
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibitionAnne Fassl, Christopher Brain, Monther Abu-Remaileh, et al.
Pageof 20

Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
The Journal of Pathology|October 15, 2013
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cellsYihui Fan, Ningling Ge, Xiaosong Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 TherapyMario Giuliano, Huizhong Hu, Yen-Chao Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2019
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Carmine De Angelis, et al.
Science Translational Medicine|March 28, 2014
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancerThushangi N Pathiraja, Shweta R Nayak, Yuanxin Xi, et al.
Breast Cancer Research : BCR|January 10, 2015
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasisMario Giuliano, Sabrina Herrera, Pavel Christiny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2019
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without ChemotherapyCarmine De Angelis, Chandandeep Nagi, Cliff C Hoyt, et al.
Developmental Cell|April 20, 2021
The bone microenvironment increases phenotypic plasticity of ER<sup>+</sup> breast cancer cellsIgor L Bado, Weijie Zhang, Jingyuan Hu, et al.
Molecular Cancer Research : MCR|August 18, 2019
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast CancerVidyalakshmi Sethunath, Huizhong Hu, Carmine De Angelis, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Science Advances|July 25, 2020
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibitionAnne Fassl, Christopher Brain, Monther Abu-Remaileh, et al.
Pageof 20